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Summary.-Regressor serum from MSV-M-infected mice markedly reduced
MSV-M oncogenesis when administered i.p. (0-1 ml/mouse) as much as 30 days
before i.m. MSV-M infection in adult BALB/c mice. The regressor serum activity
appeared to be directly dependent on the amount of IgG, as shown by: (1) inactivity
of sera which have low virus-neutralizing antibody content; (2) high effectiveness
only of the IgG serum fraction; (3) inactivity of regressor serum incubated with
anti-mouse gamma-globulin serum. The regressor serum activity was specific
and could not be ascribed to interferon or interferon-inducing factors, antigen-
antibody complexes or free antigen. The activity was not suppressed by sublethal
irradiation (380 rad) of recipient mice. These results suggest that the activity
of regressor serum administered before MSV-M infection is mediated through
sensitization of host cells which are not radiosensitive.
THE TUMOUR induced in mice by
Murine Sarcoma Virus (Moloney) (MSV-M)
is a useful model for investigating the
immunological mechanism involved in the
regression or progression of virus-induced
tumours. This tumour is known to
regress spontaneously as a result of
immunological host reactions (Fefer et al.,
1968). Mice in which the tumour has
regressed have serum virus-neutralizing
antibodies and lymphoid cells which are
cytotoxic for Moloney sarcoma cells in
vitro (Lamon, Skurzak and Klein, 1972;
Leclerc, Gomard and Levy, 1972).
Inhibition of MSV-M-induced tumour
growth by treatment with regressor serum
or its 7S fraction, administered after
infection, has been reported by several
authors (Bubenik and Turano, 1968;
Fefer, 1969; Fefer, 1970; Giuliani, Casazza
and Di Marco, 1973a).
Moreover, regressor seruim, or its 7S
fraction, induced tumour regression in
immunosuppressed mice bearing estab-
lished MSV-M-induced tumours (Giuliani
et al., 1973a). Pearson, Redman and Bass
(1973) have shown that regressor serum
is active also when administered 3 days
before challenge with tumour cells bearing
the MSV-M antigens, and suggest that the
antibody is not the only active factor in
regressor serum, since the half-life of
mouse immunoglobulin is 3-5 days (Spie-
gelberg and Weigle, 1965).
A synergistic effect between immune
sera and normal lymphoid cells has been
reported in a number of animal and
human tumours (Perlmann and Perlmann,
1970; Heppner et al., 1973; Kiesling and
Klein, 1973; Ortiz de Landazuri, Kedar
and Fahey, 1974). Sera from MSV-M
tumour-bearing mice are specifically cyto-
toxic to tumour cells in vitro, when non-
sensitized syngeneic lymphoid cells are
added (Pollack et al., 1972). Lymphoid
cells from non-sensitized mice can also be
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sensitized in vivo by passively transferred
serum from syngeneic MSV-M tumour-
bearing donors (Pollack, 1973). The sen-
sitized lymphoid cells are specifically
cytotoxic to target tumour cells in vitro.
Data. presented here show that the
injection of serum from mice in which the
MSV-M-induced tumour had completely
regressed strongly inhibited MSV-M onco-
genesis and tumour growth, even when the
serum was injected as much as 30 days
beforetheMSV-Minfection. Thisactivity
is specific and directly related to the
serum IgG content. We suggest that
IgG may act by sensitizing host immune
cells, shown not to be radiosensitive.
MATERIALS AND METHODS
Animals.-Newborn or 4-6-week-old in-
bred BALB/c mice, and 16-day-old outbred
Ha/ICR mice of the CD-1 line (received from
Charles River, Calco, Italy) were used. For
in vitro studies, secondary mouse embryo cell
cultures from Swiss NIH mice bred in our
laboratory were used.
Virus.-MSV-M, kindly provided by Dr
J. B. Moloney (National Cancer Institute,
Bethesda, Md., USA) was used for tumour
induction in adult BALB/c or CD-1 mice as
previously described (Casazza, Di Marco and
Di Cuonzo, 1971). Mice were infected by
inoculating intramuscularly (i.m.) 01 ml of
10-1 dilution of MSV-M preparation in the
right hind leg (unless otherwise stated).
The titre of the viral preparation, deter-
mined by the focus assay according to
Hirschmann et al. (1969), was 2 x 105 focus-
forming units/ml (MSV-M), 1.7% of which
was competent (MLV-MSV complex). The
percent of regression of MSV-induced
tumours in outbred CD-1 mice was around
95%; in inbred BALB/c mice, the percent of
tumour regression was around 60%. The
BALB/c mice show also a significantly high
incidence of tumour recurrence.
Columbia SK virus, an encephalomyo-
carditis virus, was kindly provided by Dr A.
Fioretti (Farmitalia Research Laboratories,
Nerviano, Italy). This virus is extremely
sensitive to interferon (Nemes and Hilleman,
1962). All animals inoculated i.p. with 10-2
dilution (10 x LD50) of the Columbia SK
virus preparation died within 10-11 days of
infection.
Tumours.-The following tumours were
used:
(a) primary tumours induced by MSV-M
infection in adult BALB/c mice, as
above described;
(b) a Moloney transplanted sarcoma (T-
MSV-M) originally induced in BALB/c
mice by i.m. infection with MSV-M.
This tumour has been maintained and
passed routinely in syngeneic hosts
for over 2 years (Giuliani, Casazza
and Di Marco, 1974);
(c) MS-2 tumours, obtained by i.m.
injection in BALB/c mice of MS-2
cells (a cell line established in vitro in
our laboratory by serial culturing of
primary MSV-M tumours) and then
maintained by in vivo passage in
syngeneic host (Giuliani et al., 1974).
The primary MSV-M and the T-MSV-M
tumours possess the viral antigens and
spontaneously regress, while MS-2 tumours
do not exhibit the viral antigens, grow
progressively and kill the host (Giuliani et al.,
1974).
Tumour measurements.-Mice were ob-
served daily, and tumour growth was
determined and graded on an arbitrary scale
of + 1 through + 4 as previously described
(Casazza et al., 1971).
Sera.-CD-1 mice were used as serum
donors, as they were available in large
numbers. Pools of sera were obtained by
cardiac puncture from uninfected (normal) or
MSV-M-infected mice, 12 (I 12) or 36 (I 36)
days after infection, or from mice treated
with daunomycin beforehand, as previously
described (Giuliani et al., 1973a).
Twelve days after infection the tumour
reached the maximal volume, and after 36
days it had completely regressed. The titre
of virus-neutralizing antibodies was maximal
in I 36 serum, but very low in I 12 serum as
previously observed (Casazza et al., 1971).
Sera wereheat-inactivated at 560 C for 30min
and stored at -20°C.
Serum fractions were obtained by separa-
tion on Sephadex G 200 column, according to
Flodin and Killander (1962). Protein elution
was detected by continuous monitoring ofthe
effluent at 280 nm. Three fractions were
obtained. Each serum fraction was con-
centrated by ultrafiltration up to the volume
of the original serum sample. Agar-gel
immunoelectrophoretic analysis was used for
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identification of IgG immunoglobulins. No
IgG was detected in the high molecular
weight Fraction I (the first peak eluted from
the column). The bulk of IgG was in
Fraction II, and only slight contamination by
IgG was observed in Fraction III.
Unfractionated sera and serum fractions
were administered to BALB/c mice i.p. in a
volume of0 1 ml/mouse 1, 6,10,15 or 30 days
before the MSV-M infection.
Rabbit anti-mouse gamma-globulin serum
was kindly provided by Dr M. I. Colnaghi
(this Institute). Regressor serum was mixed
with an equal volume of anti-mouse gamma-
globulin serum or Ringer solution, and
incubated for 30 min at room temperature.
The mixture was then injected i.p. into the
recipients (0.1 ml/mouse).
Virus-neutralization tests.-The virus-
neutralization test was carried out on Swiss
mouse fibroblast cultures, according to
O'Connor (1968). Virus + serum mixtures
were incubated at 370 C for 90 min before
cell infection. Several dilutions of serum
were used. Foci were counted 5 days after
infection. The serum activity is expressed as
Inhibiting Dose 50 (ID50), i.e., the highest
serum dilution which caused a 50% reduc-
tion offocus number, as compared to controls
(virus + normal serum mixtures).
X-irradiation.-Mice were subjected to
whole-body X-irradiation with a Philips 250
machine at 200 kV and 10 mA with 0 5 mm
Al filtration, at the dose of 148 rad/min.
The total dose administered was 380 rad.
Immediately after X-irradiation mice were
treated i.p. with 0-1 ml/mouse regressor
serum.
RESULTS
Effect ofserumfrom MSV-M-infected mice,
administered at different times before in-
fection
Serum from MSV-M-infected CD-1
mice was administered to adult BALB/c
mice at different times before MSV-M
infection. Results are reported in Table I.
I 12 serum, which has a poor virus-
neutralizing antibody content, admini-
stered 1 or 11 days before infection, was
inactive, as it was for serum of mice
infected with MSV-M and treated with
TABLE I.-Effect of Serum from MSV-M-
infected Mice on MSV-M Tumour In-
duction and Growth in Adult BALB/c
Mice*
Treatment
Time of treatment
Serum before MSV-M infection
I 12t
I 12
Normall
I 12
Normal
DS§
Normal
I 361/
Normal
I 36
Normal
I 36
Normal
I 36
Normal
I 36
4 hours
1 day
11 days
11 days
I day
1 day
1 day
1 day
6 days
6 days
10 days
10 days
15 days
15 days
30 days
30 days
Mice with
tumour/total
mice
10/10
8/8
10/10
10/10
9/10
7/9
7/8
10/10
10/10
19/19
63/65
48/49
16/57¶
10/10
10/10
5/10¶
42/50
32/39
13/46 f
27/30
9/10
9/30¶
18/20
8/10
4/20¶
* Data of several experiments. Mice were
treated i.p. with 0-1 ml serum and infected i.m. with
MSV-M.
tI 12 = serum collected 12 days after MSV-M
infection. Serum dilution giving 50% inhibition of
MSV-M focus formation in vitro = 1: 30.
t Serum from uninfected mice. Serum dilution
giving 500% inhibition of MSV-M focus formation
in vitro = 1:25.
§ DS = Serum from animals treated with
daunomycin at Days 3, 2 and 1 before the MSV-M
infection, collected 36 days after.
1a Serum collected 36 days after MSV-M infection.
Serum dilution giving 50% inhibition of MSV-M
focus formation in vitro = 1: 130.
P < 0-01 as evaluated by x2 test between
groups infected with normal and regressor serum.
daunomycin, which completely inhibited
antibody synthesis (Casazza et al., 1971).
I 36 serum, which has a high content of
virus-neutralizing antibody, markedly re-
duced oncogenesis when administered
before MSV-M infection. This activity
was long-lasting, forit was detectable when
I 36 serum was administered as much as
10, 15 or 30 days before MSV-M infection
(P < 0.01). No significant reduction of
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tumour volume was observed, compared
to controls, in the serum-treated mice
which developed tumours. Normal serum
was always devoid of activity.
Inhibition of viral oncogenesis was
observed only after administration of un-
diluted or 1:2 diluted serum; at 1:4 or
higher serum dilutions, no activity was
observed.
Lack of virus-neutralizing activity tn serum
of mice injected with regressor serum
The possibility that serum of miice
injected with regressor serum contains
antiviral antibodies has been considered.
Adult BALB/c mice were bled 3, 5, 10 and
15 days after treatment i.p. with 0-1
ml/mouse of regressor serum. No anti-
viral antibodies were detected by the in
vitro test; not even in the serum of mice
bled 3 days after treatment.
Lack of infectious MSV-M in regressor
serum, and effect of MSV-M vaccination
The possibility that regressor serum
contains viral particles able to immunize
the treated mice has been considered. No
viral activity was detected in vitro by
infection of mouse embryo cell cultures
with regressor serum in the presence of
DEAE dextran to enhance focus for-
mation (Somers and Kirsten, 1968) and
MLV-M as helper, after 3 serial passages,
or in newborn mice injected i.m. with
undiluted regressor serum and observed for
over 3 months for tumour onset.
Vaccination with live MSV-M i.p. had
to be carried out at fairly high concen-
tration to elicit an effect similar to that
due to regressor serum. Data reported in
Table II show that vaccination with live
MSV-M (titre of virus stock: 2 x 105
focus forming units/ml) carried out 3 days
before the MSV-M infection, was active
only at the 10-1 dilution (P < 0-01).
10-1 and 10-2 dilutions, but not 10-3, were
active when administered 15 days before
MSV-M infection.
Effect ofserumfractions on MSV-M tumour
induction and growth
Regressor serum was fractionated on
Sephadex G 200 column. Three fractions
were obtained. Serum fractions were
administered i.p. to BALB/c mice 1 day
(2 experiments) or 10 days before MSV-M
infection. Results are shown in Table
III. Only Fraction II, which contained a
large amount of IgG and had the highest
virus-neutralizing antibody content, was
active (P < 0-01 and P < 0.05). The
activity of Fraction II was significant
when administered both 1 and 10 days
before the MSV-M infection.
TABLE II. Effect of Vaccination with Live MSV-M on MSV-M Tumour Induction in
Adult BALB/c Mice
Vaccination*
MSV-M Time before the
dilutiont infection (days)
0--1
10- 2
10-3
10-1
10- 2
10-3
3
3
3
15
15
15
Mice with
tumour/total
mice
9/9
3/10t
7/10 (NS)
10/10 (NS)
10/10
4/9§
3/10§
9/1o(NS)
Tj ±s.e.
(days)
5 - 6±0*5
140±3 3
5-7±0-9
5*2±0-4
4 7±0 3
38 0±7 0
44 -0±5 * 7
5-6±0-9
* Mice were treated i.p. with MSV-M at the given dilution, and injected i.m. with 10-1 MSV-M dilution
3 or 15 days after.
t A virus stock having a titre of 2 x 105 focus-forming units/ml (MSV) was lused, 1-7% of which was
competent (MLV-MSV complex).
I Mean time to onset of palpable tumour after infection.
§ P < 0-01 as evaluated by x2 test.
NS = Not significant.
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TABLE III.-Activity of Serum Fractions on MSV-M Tumour Induction and Growth in
Adult BALB/c Mice
Pt:
<0-01
<0-05
NS
<0-01
NS
Tt ±s.e.
(days)
5-4±0-2
4-8±0-5
11-0±1-8
4-2±0-2
5-5±0-2
7-6±1-4
4-4±0-3
9-9±1 0
26-0±9-6
8-0±0-8
9-8±1 i 7
Maximum tumour
size
(average)§
3-8
4-0
1-2
3-9
3-8
1-9
4-0
3-1
2-0
0-3
2-2
Phl
NS
<001
NS
<0-05
NS
NS
<0-01
NS
* Serum fractions were obtained by fractionation on Sephadex column (see " Materials and Methods "),
and injected i.p. (0-1 ml/mouse) 1 or 10 days before MSV-M infection.
** The serum dilution giving 50% inhibition on MSV-M focus formation in vitro.
I Significance evaluated by x2 test.
t Mean time to onset ofpalpable tumour after infection.
§ Arbitrary units (see " Materials and Methods ").
11 Significance evaluated by Student's t test.
NS = Not significant.
TABLE IV.-Suppression of Regressor Serum Activity by Incubation with
mouse Gamma-globulin Serum
Mice with Ma
tumour/total
Treatment* mice P:
20/20 -
Regressor Serumt 1/10 <0*01
Regressor serum + Ringer 3/10 NS
Anti-mouse gamma-globulin serum + Ringer 10/10 NS
Regressor serum + anti-mouse gamma-globulin serum 8/10 NS
Rabbit Anti-
iximum tumour
size
(average) §
4-0
0-1
1.0
3-9
2-5
* AdultBALB/c mice wereinoculatedi.p. with 0-1 ml/mouse ofserum or serummixtures, 10daysbeforei.m.
MSV-M infection. Mixtures were incubated at room temperature for 30min (see " Materials and Methods ").
t Serum collected 36 days after MSV-M infection.
t Evaluated by x2 test.
§ Arbitrary units.
Suppression of regressor serum activity by
rabbit anti-mouse gamma-globulin serum
In order to find out whether the
activity of regressor serum depended on
the antibody content, the serum was
incubated at room temperature for 30
min with an equal volume of rabbit anti-
mousegamma-globulin serum andadminis-
tered to BALB/c mice 10 days before the
MSV-M infection. Results reported in
Table IV show that incubation of regres-
sor serum with anti-mouse gamma-
globulin serum significantly (P < 0-01)
reduced the serum protecting activity.
Specificity of regressor serum activity
Experiments were performed to test
the specificity ofthe immune serum. The
serum effect was studied in mice injected
with T-MSV-M tumours, which possess the
viral antigens, and in mice injected with
MS-2 tumours, which are free of viral
antigens. Serum treatment performed 10
days before tumour implantation con-
siderably lowered the mortality (P < 0.01)
ofmice challenged with T-MSV-M tumour,
while no effect was demonstrated on MS-2
tumours (Table V).
Effect of regressor serum in immuno-
depressed adult mice
Immunodepressed adult BALB/c mice
were treated with regressor serum 1 or 10
days before the MSV-M infection. Mice
Serum
fractions*
I
II
III
II
III
I
II
III
Day of
treatment
before
MSV-M
infection
1
1
1
1
1
10
10
10
ID50**
1:30
1:85
1:15
1:70
1:10
1:30
1:85
1:15
Mice with
tumour/total
mice
10/10
10/10
4/10
10/10
10/10
5/10
10/10
10/10
4/5
1/9
7/10
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TABLE V.-Specificity of Regressor Serum Activity: Effect on T-MSV-M and MS-2
Tumours*
Challenge
Challenging No. of tumour
tumours cells
T-MSV-Mt 104
104
105
105
MS-2t 103
103
104
104
105
105
Mice with
Serum tumour/total
treatment mice
10/10
+ 8/10
10/10
+ 9/10
- 6/10
+ 5/7
- 10/10
+ 10/10
10/10
+L 10/10
* All mice were treated i.p. with regressor serum 10 days before i.m. tumour cell inoculation.
t See " Materials and Methods ".
I % mortality refers to mice dying with progressively growing tumours.
§ Evaluated by x2 test.
were infected with different viral dilutions.
Results are summarized in Table VI. In
irradiated (380 rad) adult BALB/c mice
infected with 10-1 MSV-M dilution, ad-
ministration of regressor serum one day
before infection did not decrease the
number of mice developing tumours nor
the mortality, but delayed tumour onset
and significantly increased survival time.
Regressor serum reduced the percentage of
mice with tumour, when given one day
before irradiated mice were infected with
low viral doses (MSV-M diluted 10-2 and
2 x 10-3). Similar results were obtained
with X-irradiated mice, by serum treat-
ment 10 days before MSV-M infection.
Normal serum was always included in the
experiments and was constantly found
inactive.
Inactivity of regressor serum on Columbia
SK virus infection
In order to test for the presence of
interferon or interferon-inducing factors,
regressor serum was administered to
BALB/c mice 1 or 10 days before infection
with Columbia SK virus. No protection
was observed.
DISCUSSION
The data presented in this paper
demonstrate that MSV-M regressor serum
containing virus-neutralizing antibodies
confers significant resistance against MSV-
M tumour induction, when administered
early as one month before MSV-M in-
fection.
Administration of 0-1 ml/mouse of
regressor serum, 1, 6, 10, 15 or 30 days
before MSV-M infection greatly reduced
oncogenesis.
Previous studies on lymphoid cells
from mice in which the MSV-M tumours
had regressed, indicated that these lym-
phoid cells contain infecting MSV-M
(Giuliani et al., 1973b). However, no
virus was detected in regressor serum by
infection of mouse embryo cells cultures
in vitro or by i.m. injection of newborn
mice. On the other hand, the results of
vaccination with live MSV-M demon-
strated that a large amount of virus was
needed to exert an effect comparable to
that of regressor serum.
The hypothesis that interferon or
interferon-inducing factors are present in
regressor serum, was ruled out by experi-
ments on Columbia SK virus infection,
which is very sensitive to interferon
(Nemes and Hilleman, 1962).
The serum obtained from MSV-M-
infected mice 12 days after infection, when
the tumour reached its maximum volume,
did not contain MSV-M-neutralizing anti-
bodies. However, this serum may contain
Mortality:
60
10
100
30
60
71
100
100
100
100
P§
<0*01
<O0*01
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blocking factors (Hellstrom and Hellstrom,
1970) in the form of free antigens (Brawn,
1971) or antigen-antibodies complexes
(Sjogren et al., 1971). Thus, in our study,
the lack of effect on tumour induction and
growth of I 12 serum administered 11 days
before the MSV-M infection, suggests that
the activity of regressor serum was not
due to the presence of immuno-complexes
or free antigens.
Regressor serum activity appears to be
directly related to the quantity of virus-
neutralizing antibody, as shown by:
(1) the inactivity of sera which have a
low virus-neutralizing antibody
content, such as the I 12 serum or
the serum from mice treated with
daunomycin, which completely in-
hibited antibody synthesis;
(2) the high effectiveness only of
Fraction II which contains a large
amount of IgG;
(3) the inactivity of regressor serum
incubatedwithanti-mouse gamma-
globulin serum.
On the base of a study on the cata-
bolism of gamma-globulin fragments,
mouse gamma-globulins are reported to
have a half-life of 3-5 days (Spiegelberg
and Weigle, 1965). It is reasonable to pre-
sume that the serum activity observed is
not a direct effect of antibodies on target
cells and/or on the virus, since the level
of gamma-globulins would be very low
30 days after the immune serum injection.
Actually, in vitro neutralization tests
carried out on mice previously treated
with regressor serum, showed the lack of
virus-neutralizing antibodies already 3
days after the serum treatment.
We tested the effect of regressor serum
on mice injected with MSV-M transplanted
tumours, which possess viral antigens, or
with MS-2 tumour, which does not con-
tain the viral antigens. Serum treatment
was active only on the first tumour
system. This finding is consistent with a
specificity of the regressor serum.
The results obtained suggest that
14
antibodies (and specifically IgG) from
mice in which the MSV-M-induced tumour
has regressed, when injected into intact
mice, render them resistant to subsequent
challenge with MSV-M, by specific sen-
sitization of some immune cell population.
This hypothesis is supported by the
demonstration in vitro that lymphoid cells
participate in a specific cytotoxic reaction
against tumour cells by tumour-specific
antibody (Pollack et al., 1972; Pollack and
Nelson, 1974; Stolfi et al., 1974). More-
over, the arming factor present in immune
serum has been identified as IgG (Mac
Lennan, Loewi and Howard, 1969; Perl-
mann, Perlmann and Biberfeld, 1972;
Greenberg and Shen, 1973; Pollack and
Nelson, 1974).
The experimentsinadult mice immuno-
suppressed by previous exposure to X-
irradiation, have shown that regressor
serummaintainsits activityinX-irradiated
mice, even if somewhat reduced. This
suggests that any host factors partici-
pating in this protection are radioresistant.
It has been shown that macrophages and
subpopulations of lymphoid cells may be
resistant to X-irradiation (Schrek, 1961;
Kettman and Dutton, 1971; Haot, Betz
and Resvesz, 1973).
Experiments are in progress to identify
the relevant viral antigens carried by the
MSV-M or MLV virus particles responsible
for the effects observed, and to find out
whether macrophages, or other immune
radioresistant cell populations, are host
factors involved in this protection.
Preliminary results suggest that re-
gressor serum does not protect against the
MSV-M-induced sarcoma in mice pre-
viously treated with two specific anti-
macrophage agents: trypan blue and
silica.
The authors are indebted to Dr R. A.
Gambetta for serum fractionation, Mr A.
Ubaldi for capable assistance, Miss M. A.
Rapuano for secretarial assistance and the
Service of Health Physics of the Institute
for X-irradiation.
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